期刊
JOURNAL OF CANCER
卷 12, 期 9, 页码 2747-2755出版社
IVYSPRING INT PUBL
DOI: 10.7150/jca.57019
关键词
breast cancer; early diagnosis; biomarker; autoantibody
类别
资金
- Natural Science Foundation of China [81972801]
- Natural Science Foundation of Guangdong Province [2018A030307079, 2018A0303130279, 2019A1515011 873]
- Guangdong Esophageal Cancer Institute Science and Technology Program [Q201906]
- Medical Project of Science and Technology Planning of Shantou [200605115266724, 2017/166]
- Guangdong Provincial Key Laboratory for Breast Cancer Diagnosis and Treatment [2017B030314116]
- Science and Technology Special Fund of Guangdong Province of China [190829105556145, 180918114960704]
- 2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant [2020LKSFG01B]
A panel of autoantibodies targeting BMI-1, HSP70, NY-ESO-1, and p53 showed potential in detecting early stage breast cancer with high sensitivity and specificity.
We previously found a panel of autoantibodies against multiple tumor-associated antigens (BMI-1, HSP70, MMP-7, NY-ESO-1, p53 and PRDX6) that might facilitate early detection of esophagogastric junction adenocarcinoma and esophageal squamous cell carcinoma. Here we aimed at assessing the diagnostic performance of these autoantibodies in breast cancer patients. Enzyme-linked immunosorbent assay was applied to detect sera autoantibodies in 123 breast cancer patients and 123 age-matched normal controls. We adopted logistic regression analysis to identify optimized autoantibody biomarkers for diagnosis and receiver-operating characteristics to analyze diagnostic efficiency. Five of six autoantibodies, BMI-1, HSP70, NY-ESO-1, p53 and PRDX6 demonstrated significantly elevated serum levels in breast cancer compared to normal controls. An optimized panel composed of autoantibodies to BMI-1, HSP70, NY-ESO-1 and p53 showed an area under the curve (AUC) of 0.819 (95% CI 0.766-0.873), 63.4% sensitivity and 90.2% specificity for diagnosing breast cancer. Moreover, this autoantibody panel could differentiate patients with early stage breast cancer from normal controls, with AUC of 0.805 (95% CI 0.743-0.886), 59.6% sensitivity and 90.2% specificity. Our findings indicated that the panel of autoantibodies to BMI-1, HSP70, NY-ESO-1 and p53 as serum biomarkers have the potential to help detect early stage breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据